维立志博-B(09887.HK)：LBL-024于铂耐药卵巢癌IB/II期试验的首例患者用药
LEADS BIOLABS-BLEADS BIOLABS-B(HK:09887) Ge Long Hui·2025-12-23 08:35

Core Viewpoint - The announcement highlights the successful administration of LBL-024, a PD-L1/4-1BB bispecific antibody, in the first patient of a Phase Ib/II clinical trial for platinum-resistant ovarian cancer [1] Group 1: Clinical Trial Details - The clinical trial is an open-label, multicenter Phase Ib/II study led by Professor Wu Lingying from the Cancer Hospital of the Chinese Academy of Medical Sciences [1] - The trial is being conducted simultaneously across multiple hospitals in China [1] - The objective of the trial is to evaluate the efficacy and safety of LBL-024 in combination with paclitaxel for patients with platinum-resistant ovarian cancer [1]

LEADS BIOLABS-B-维立志博-B(09887.HK)：LBL-024于铂耐药卵巢癌IB/II期试验的首例患者用药 - Reportify